Tepnel sees turnover rise again:
This article was originally published in Clinica
UK diagnostics developer Tepnel Life Sciences has reported sales of £140,000 ($210,000) for the six months to March 31st, 1996, up from £50,000 in the previous six-month period. The company was able to reduce its operating loss to £526,000 from £953,000.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.